Navigation Links
Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Date:11/3/2010

EAST HANOVER, N.J., Nov. 3, 2010 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor® (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS)(1,2). This study, which was previously presented at the 46th American Society of Clinical Oncology annual meeting, is the first prospective clinical trial of a drug to show treatment benefit in these patients.

Tuberous sclerosis is a genetic disorder that is estimated to affect 25,000 to 40,000 people in the US and may cause benign tumors to form in vital organs(3). SEGAs, benign brain tumors, occur in up to 20% of patients with TS and primarily affect children and adolescents(1,4,5). SEGAs may pose a significant medical risk, including the potential for swelling in the brain, or hydrocephalus(1).

According to data published in NEJM from this Phase I/II study of 28 patients conducted by Cincinnati Children's Hospital Medical Center, treatment with everolimus was associated with a significant reduction in primary SEGA volume at six months relative to baseline on independent central review (p<0.001). Seventy-five percent of patients (21 of 28) experienced a reduction of 30% or greater in the size of their largest SEGA and 32% (9 of 28) experienced a reduction of 50% or greater at six months relative to baseline(2).

The published study findings also showed that in nine of 16 patients, everolimus therapy was associated with a reduction from baseline to six months in overall frequency of seizures per 24 hour video electroencephalograms (EEG) (n=16; median change -1 seizure, p=0.022). Additionally, no patients required surgery or developed a new SEGA while receiving everolimus(2).

The most common adverse reactions observed (incidence greater than or equal to 30%) in this trial were mouth sores,
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 /PRNewswire/ ... needs of customers who are increasingly mobile, increasingly connected, ... support a growing variety of customer interaction channels and ... of technology, including social media. According ... of the over the counter (OTC) segment in a ...
(Date:7/31/2015)... More than 1,500 substance abuse prevention and treatment specialists ... Indianapolis Aug. 2-6 for Community Anti-Drug Coalitions ... The week-long training, held at the JW Marriott, will ... biggest public health challenges – youth drug use. ... intensive training opportunity, offering more than 70 half-day and ...
(Date:7/31/2015)... RnRMarketResearch.com adds Syringes and ... that provides an overview of syringes and needles ... in-house databases, secondary and primary research. ... pipeline spread across 124 pages, talking about 13 ... 5 figures is now available at http://www.rnrmarketresearch.com/syringes-and-needles-pipeline-review-2015-market-report.html ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... Inc. (Nasdaq: VRUS ) has received fast track ... PSI-938 for the treatment of chronic hepatitis C virus (HCV) ... of HCV. In March 2011, Pharmasset presented ... antiviral activity and is generally safe and well tolerated, both ...
... The concept of smaller, thinner laparoscopic tools has ... since the advent of laparoscopic surgery. Some prominent manufacturers ... past, but they did not perform to the standard ... how the extremely thin instruments would bend under the ...
Cached Medicine Technology:PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 2PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 3New Micro Laparoscopic Instruments for the Bariatric Surgery Allow for Less Scarring and Pain than Ever Before Possible 2
(Date:8/1/2015)... ... , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked over ... was greeted by friends and family. He visited CCAR and left an inspirational message ...
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in ... each year is the Super Bowl. In the two weeks that separate the conference championships ... venue. The 2016 Super Bowl game will mark the 50th time it has been held ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On ... on October 3, 2015. The Ride to Fight On is a cycling fundraiser that ... Healthcare, The West Clinic and The University of Tennessee Health Science Center. A health ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Coco Libre announced ... judges, media, and VIPs at the 2015 Vans US Open of Surfing, July 25 ... that can claim “no added sugar” on the market, is a natural choice given ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... , August is National Immunization Awareness ... 3 Department of Health Secretary Everette James today stressed ... Month. , , "Recommended vaccinations begin soon ... your family are up-to-date on these immunizations is critical to ...
... odds for chronic illness, review finds , MONDAY, Aug. 3 ... greater risk of developing kidney disease later in life, according ... found that people who were less than 5.5 pounds at ... disease than those with normal birth weight. The findings appear ...
... over their usefulness , MONDAY, Aug. 3 (HealthDay News) -- ... masks to ward off the flu, and the results of ... , Researchers in Hong Kong found that wearing a surgical ... transmission rates for the seasonal flu down, at least among ...
... , TEMPLE, Texas, Aug. 3 Scott ... at a national conference in Washington, DC titled "How Do They Do ... the only Texas health care system and one of 10 health systems ... , , The event was jointly hosted by The ...
... , , BEDFORD, Mass., Aug. 3 ... manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to ... June 27, 2009. , , Highlights of the quarter include: ... Revenues of $403.1 million. , Third quarter 2009 net income ...
... , , , , ... Uroplasty, Inc. (NYSE Amex: UPI ), a medical device ... dysfunctions, today reported financial results for the first fiscal quarter ended June ... the strategy we communicated at the beginning of the fiscal year of ...
Cached Medicine News:Health News:Corrected: Secretary of Health Urges Pennsylvanians to Get Immunized 2Health News:Corrected: Secretary of Health Urges Pennsylvanians to Get Immunized 3Health News:Low Birth Weight Might Raise Adult Kidney Disease Risk 2Health News:Surgical Masks Help Ward Off Flu, Maybe 2Health News:Surgical Masks Help Ward Off Flu, Maybe 3Health News:Surgical Masks Help Ward Off Flu, Maybe 4Health News:Scott & White Leadership Invited to National Forum on High Quality, Low-Cost Health Care 2Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 2Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 3Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 4Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 5Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 6Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 7Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 8Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 9Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 10Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 11Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 12Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 13Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 14Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 15Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 16Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 17Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 18Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 19Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 20Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 21Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 22Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 23Health News:Uroplasty Reports First Fiscal Quarter Results 2Health News:Uroplasty Reports First Fiscal Quarter Results 3Health News:Uroplasty Reports First Fiscal Quarter Results 4Health News:Uroplasty Reports First Fiscal Quarter Results 5Health News:Uroplasty Reports First Fiscal Quarter Results 6Health News:Uroplasty Reports First Fiscal Quarter Results 7
For the qualitative determination of magnesium in serum....
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Medicine Products: